Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

fludarabine phosphate 38Peripheral Blood Stem Cell Transplantation 35Whole-Body Irradiation 30Mycophenolic Acid 29Cyclophosphamide 27Tacrolimus 21Cyclosporine 20Busulfan 17Antilymphocyte Serum 14Methotrexate 13Melphalan 12Sirolimus 9Radiotherapy 8Filgrastim 8Etoposide 8Cyclosporins 8Cord Blood Stem Cell Transplantation 6Transplantation 5Methylprednisolone 5Bortezomib 5sargramostim 4Therapeutics 4Everolimus 4Epoetin Alfa 4Cytarabine 4Carboplatin 4thymoglobulin 3fludarabine 3Thiotepa 3Rituximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × CB-839 × Plasma cell × Clear all
NCT02071888 2018-07-18

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Calithera Biosciences, Inc

Phase 1 Completed
25 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡